Discounted Cash Flow

Niagen Bioscience, Inc.

NAGE · Based on 10 years of SEC filings · Converted from GBP to USD

—

⚠ Cash flow predictability 42/100 (moderate) — FCF YoY std dev 74%, net income 73% (full history)

▲ Accelerating sales growth

Sales growth has accelerated: 6.8% (2022) → 16.0% (2023) → 19.2% (2024) → 29.9% (2025). Revenue growth has been accelerating in recent years and is now 29.9% — rapidly accelerating growth may be difficult to sustain at this pace, or the DCF (based on historical averages) may understate future momentum.

Average annual growth rates

Metric	10-Year	5-Year	3-Year
Sales	—	—	—
Free Cash Flow	—	—	—
Average (FCF & NI)	—	—	—
Net Income	—	—	—
Dividends	—	—	—

Average annual growth is the mean year-over-year change across each period.

Endpoint CAGR (better for long term trend)

Metric	10-Year	5-Year	3-Year
Sales	—	—	—
Free Cash Flow	—	—	—
Average (FCF & NI)	—	—	—
Net Income	—	—	—

Endpoint CAGR is the compound annual rate from the first to last year in each period.

Projections use average year-over-year growth. Change this in Settings.

Projected growth rate

—

Free cash flow growth —

10-year: — 5-year: — 3-year: —

Averaged growth (FCF & NI) —

10-year: — 5-year: — 3-year: —

Net income growth —

10-year: — 5-year: — 3-year: —

Sales growth (not added to calculations) —

10-year: — 5-year: — 3-year: —

Click a greyed-out slider to switch metrics. Slide between the 10-year, 5-year, and 3-year historic growth rates for FCF, net income, or their average.

Or enter your own rate

Inflation rate (used with B/E only)

Historical inputs (10 fiscal years)

YEAR	Sales	Net Income	Free Cash Flow	Net Margin	EPS (diluted)
2016	$36.2m	$-4.0m	$-6.0m	-10.9%	$-0.03
2017	$28.7m (-20.9%)	$-15.4m (-288.6%)	$-14.8m (-147.0%)	-53.7% (-391.4%)	$-0.26 (-766.7%)
2018	$42.7m (48.8%)	$-45.0m (-192.8%)	$-30.1m (-102.6%)	-105.6% (-96.7%)	$-0.61 (-134.6%)
2019	$62.6m (46.7%)	$-43.5m (3.5%)	$-28.6m (4.7%)	-69.4% (34.2%)	$-0.56 (8.2%)
2020	$80.1m (28.0%)	$-26.9m (38.0%)	$-14.4m (49.7%)	-33.6% (51.6%)	$-0.33 (41.1%)
2021	$91.2m (13.8%)	$-36.7m (-36.2%)	$-32.7m (-126.9%)	-40.2% (-19.6%)	$-0.40 (-21.2%)
2022	$97.4m (6.8%)	$-22.4m (39.0%)	$-20.9m (36.1%)	-23.0% (42.9%)	$-0.24 (40.0%)
2023	$113.0m (16.0%)	$-6.7m (70.1%)	$9.4m (145.2%)	-5.9% (74.3%)	$-0.07 (70.8%)
2024	$134.7m (19.2%)	$11.6m (273.1%)	$16.2m (71.4%)	8.6% (245.3%)	$0.11 (257.1%)
2025	$175.0m (29.9%)	$23.5m (103.3%)	$17.9m (10.6%)	13.4% (56.4%)	$0.22 (100.0%)

Base FCF: — (latest fiscal year)

Discount rate: %

Terminal growth: —

Projection period: — years

Alt A decline yrs:

Alt B total yrs:

SEC filings report in GBP. Values above are converted to USD for comparison with the US-listed share price.

Projected cash flows

Year	Projected cash flow	Discount Factor	Present Value

PV of projected FCF: —

Terminal FCF: —

Terminal value: —

PV of terminal value: —

Enterprise value (DCF): —

Current price: —

Alternative DCF Models

Model	Fair Value	Upside	PV(FCFs)	PV(Terminal)	Total Years
Standard (10yr→TV) ⓘ	—	—	—	—	10 + TV
Alt A (Gradual Decline) ⓘ	—	—	—	—	—
Alt B (30yr Hard Stop) ⓘ	—	—	—	N/A	—

This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.

+ 10YR Financials Balance Sheet (10YR) Cash Flow (10YR) DCF Model